LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

SAVE THE DATE: EFIB 2022 goes to Vilnius, Lithuania

24/01/2022
PRESS RELEASE
Brussels, 24 January 2021 – EuropaBio is pleased to announce that the next edition of EFIB, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title‘Next generation economies: Industrial biotechnology for a sustainable society’, will take place 26-27 October 2022 in Vilnius, Lithuania. The Forum will be hosted by the Lithuanian Biotechnology Association (LBTA) together with Go Vilnius – the city’s official business and tourism development agency.

Now in its 15th year, EFIB will be dedicated to the innovation and commercial delivery of industrial biotechnology and the bioeconomy. EFIB will include a pre-conference science symposium ’’Gene Editing – From Research To Industry’’, followed by two day Forum discussing how Industrial biotechnology contributes to transforming sectors and addresses consumer choices and needs.

‘After a successful 2021 in person edition, which discussed how our companies can help to deliver the EU Green Deal, we are exploring how industrial biotechnology advances contribute to the next generation economies and creating more sustainable societies. Lithuania is an outstanding location and a growing hotspot for Life Sciences in Europe, which makes it a perfect destination for our community to gather together and search for new synergies.’ said Dr Claire Skentelbery, Director General of EuropaBio.

The conference will network and showcase more than 500 delegates from the industry of all sizes, from start-ups with the next transformative technology to multi-national producers scaling up to meet global demand for sustainable and novel products across sectors. It will also bring together the community that enables the industry to deliver, including the researchers, policy makers, academia, regulators, global organisations and local leaders that build the framework for a sustainable society.

“EFIB 2022 pre-conference will reflect the great potential of gene editing technologies, like CRISPR Cas, for which Lithuania is widely known for, and will cover the successful stories how gene editing research outcomes were turned into successful applications with the remarkable impact on the future of the life sciences industry.“ Said Dr Monika Paule, CEO of CasZyme & LBTA Board Member.

For the first time in 2022, EFIB will host a post-conference meeting in the Permanent Representation of Lithuania to the EU in Brussels on 30 November, which will deliver the EFIB Vilnius Statement to policy makers at the heart of Europe.

The registration for the EFIB 2022 will be opened in March. For more information please visit our website and subscribe to our newsletter.

Are you interested in sponsorship opportunities?
EFIB offers an opportunity for sponsor organisations to achieve key objectives, including sector messaging and advocacy or products and services visibility. For more information please contact Dr Claire Skentelbery, Director General of EuropaBio (c.skentelbery@europabio.org).

SAVE THE DATE: EFIB 2022 goes to Vilnius, Lithuania


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more
25/06/2025

Hawkwood Biotech joins EuropaBio: Supporting Industrial Biotech with their Critical Challenges


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.